摘要
目的探讨阿帕替尼联合希罗达治疗一、二线治疗失败的晚期三阴性乳腺癌的临床意义。方法回顾性分析我院2015年10月-2017年4月收治的53例晚期三阴性乳腺癌患者的临床资料,根据治疗方法不同分为观察组26例,对照组27例。观察组患者应用阿帕替尼250 mg,口服,1次/d,希罗达1 250 mg/m^2,口服,2次/d,连用两周,休息一周,直至病情进展;对照组患者应用希罗达1 250 mg/m^2,口服,2次/d,连用两周,休息一周,直至病情进展。比较阿帕替尼联合希罗达和单药希罗达的客观缓解率、疾病控制率及不良事件差异有无统计学意义。结果客观缓解率和疾病控制率观察组显著高于对照组,差异均有统计学意义。除了1~2级高血压、1~2级出血外,其他不良事件差异无统计学意义。结论对于晚期三阴性乳腺癌患者,一线、二线治疗无法控制疾病进展,可考虑应用阿帕替尼联合希罗达治疗替代希罗达单药治疗,并且阿帕替尼联合希罗达的副反应可耐受。
Objective To explore the clinical significance of apatinib combined with Xeloda in the treatment of advanced triple negative breast cancer.Methods Fifty-three cases with advanced triple negative breast cancer from October 2015 to April 2017 in Tangshan People’s Hospital were selected and were divided into two groups according to different treatment.Twenty-six patients in the observation group were treated with apatinib 250 mg once a day,Xeloda 125 mg/m^2,orally,twice a day,for two weeks,rest for one week until the progress of the disease;27 patients in the control group were treated with Xeloda 125 mg/m^2,orally,twice a day,for two weeks,rest for one week until the progress of the disease.The objective remission rate,disease control rate and adverse events of apatinib combined with Xeloda and single drug Xeloda were compared.Results The objective remission rate and disease control rate in the observation group were significantly higher than that in the control group,and the difference was statistically significant.There was no significant difference in other adverse events except 1-2 grade hypertension and 1-2 grade hemorrhage.Conclusion For advanced triple negative breast cancer patients,the first-line and second-line treatment can not control the progress of the disease,we can consider the use of apatinib combined with Xeloda instead of single drug treatment of Xeloda,and the side effects of apatinib combined with Xeloda are tolerable.
作者
李义慧
王雨薇
周洋
王建功
杨俊泉
Li Yihui;Wang Yicuuei;Zhou Yang(Department of Comprehensive Treatment of Tumor,Tangshan People's Hospital,Tangshan 063000,China)
出处
《中国煤炭工业医学杂志》
2019年第6期598-601,共4页
Chinese Journal of Coal Industry Medicine
基金
河北省医学科学研究重点课题计划(编号:20181208)
关键词
阿帕替尼
希罗达
晚期三阴乳腺癌
Apatinib
Xeloda
Advanced triple negative breast cancer
